Rhumbline Advisers Ampio Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$0.16 - $0.47 $26,324 - $77,329	-164,531 Closed	0 $0
Q1 2022 May 12, 2022	BUY	$0.42 - $0.62 $7,872 - $11,621	18,744 Added 12.86%	164,531 $77,000
Q4 2021 Feb 10, 2022	SELL	$0.56 - $1.71 $2,282 - $6,969	-4,076 Reduced 2.72%	145,787 $83,000
Q3 2021 Nov 12, 2021	BUY	$1.21 - $1.8 $10,829 - $16,110	8,950 Added 6.35%	149,863 $249,000
Q2 2021 Aug 05, 2021	BUY	$1.56 - $1.98 $219,824 - $279,007	140,913 New	140,913 $235,000

Q2 2019 Aug 14, 2019	SELL	$0.39 - $0.7 $42,790 - $76,802	-109,718 Closed	0 $0
Q1 2019 May 01, 2019	SELL	$0.43 - $0.68 $909 - $1,438	-2,115 Reduced 1.89%	109,718 $62,000
Q4 2018 Jan 31, 2019	BUY	$0.39 - $0.7 $15,459 - $27,748	39,640 Added 54.91%	111,833 $44,000
Q3 2018 Nov 07, 2018	BUY	$0.44 - $3.02 $970 - $6,662	2,206 Added 3.15%	72,193 $37,000
Q2 2018 Aug 06, 2018	BUY	$1.66 - $3.82 $116,178 - $267,350	69,987 New	69,987 $154,000

96.6K

Ticker AMPE
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 226,287,008
Market Cap $24.9M
Description
Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.